Evidence map›Paper›PMID 36093376›Full record

ArticleiScience2022

Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants.

Jing Xing, Rama Shankar, Meehyun Ko, Keke Zhang, Sulin Zhang, Aleksandra Drelich, Shreya Paithankar, Eugene Chekalin, Mei-Sze Chua, Surender Rajasekaran and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jing XingDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Rama ShankarDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Meehyun KoZoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Korea.
Keke ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Sulin ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Aleksandra DrelichDepartments of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Shreya PaithankarDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Eugene ChekalinDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Mei-Sze ChuaDepartment of Surgery, Stanford University School of Medicine, Palo Alto, CA, USA.
Surender RajasekaranDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Chien-Te Kent TsengDepartments of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Mingyue ZhengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Seungtaek KimZoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488, Korea.
Bin ChenDepartment of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.

Funding

Repurpose open data to discover therapeutics for understudied diseasesR01GM134307 · NIGMS · MICHIGAN STATE UNIVERSITY · PI CHEN, BIN · 2019 to 2023
$2.5M
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancersK01ES028047 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, BIN · 2017 to 2020
$682k
NIEHS NIH HHS K01 ES028047NIGMS NIH HHS R01 GM134307
6 · The paper itself

Abstract

The molecular manifestations of host cells responding to SARS-CoV-2 and its evolving variants of infection are vastly different across the studied models and conditions, imposing challenges for host-based antiviral drug discovery. Based on the postulation that antiviral drugs tend to reverse the global host gene expression induced by viral infection, we retrospectively evaluated hundreds of signatures derived from 1,700 published host transcriptomic profiles of SARS/MERS/SARS-CoV-2 infection using an iterative data-driven approach. A few of these signatures could be reversed by known anti-SARS-CoV-2 inhibitors, suggesting the potential of extrapolating the biology for new variant research. We discovered IMD-0354 as a promising candidate to reverse the signatures globally with nanomolar IC

Indexed as

BioinformaticsMicrobiologyOmicsTranscriptomicsVirology

Identifiers

PMID36093376
PMCPMC9439871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.